Karyopharm Therapeutics Inc. has released a corporate presentation outlining key developments for 2026. The presentation highlights the company's lead asset, XPOVIO® (selinexor), which is now approved in over 50 countries and is being evaluated for additional indications. Top-line data from two Phase 3 trials are anticipated in 2026: the SENTRY trial of selinexor plus ruxolitinib in myelofibrosis, with results expected in March, and the XPORT-EC-042 trial of selinexor in endometrial cancer, with results expected mid-year. Karyopharm projects that selinexor could reach a peak annual revenue opportunity of up to approximately $1 billion in myelofibrosis, pending positive trial results and regulatory approval. The company also notes its existing commercial infrastructure in the U.S., which is positioned to support future product launches. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.